MNTA musings: My local CVS pharmacist knows nothing about WPI’s generic Lovenox and says there is no entry for such a product on the company’s computer system. (According to its Lovenox agreement with Amphastar, WPI is handling the retail pharmacy channel.)
Moreover, MNTA’s IR department, which is normally responsive to shareholder inquiries, appears to have gone into radio silence.
None of this is probative one way or the other, but it is curious.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”